North America Cardiac Biomarkers Market Size & Outlook
North America cardiac biomarkers market, 2018-2030 (US$M)
North America cardiac biomarkers market highlights
- The North America cardiac biomarkers market generated a revenue of USD 10,022.7 million in 2024.
- The market is expected to grow at a CAGR of 14.6% from 2025 to 2030.
- In terms of segment, troponin was the largest revenue generating type in 2024.
- Troponin is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 10,022.7 million |
| Market revenue in 2030 | USD 22,618.6 million |
| Growth rate | 14.6% (CAGR from 2025 to 2030) |
| Largest segment | Troponin |
| Fastest growing segment | Troponin |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Troponin, CK-MB, Myoglobin, BNP and NT-proBNP |
| Key market players worldwide | Abbott Laboratories, QuidelOrtho Corp, Siemens Healthineers AG ADR, Roche Holding AG ADR, Danaher Corp, BioMerieux SA, Bio-Rad Laboratories Inc, Randox, Creative Diagnostics, Life Diagnostics |
Other key industry trends
- In terms of revenue, North America region accounted for 43.1% of the global cardiac biomarkers market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 12,541.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Biomarkers Market Scope
Cardiac Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America cardiac biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac biomarkers market will help companies and investors design strategic landscapes.
Troponin was the largest segment with a revenue share of 40.87% in 2024. Horizon Databook has segmented the North America cardiac biomarkers market based on troponin, ck-mb, myoglobin, bnp and nt-probnp covering the revenue growth of each sub-segment from 2018 to 2030.
North America is estimated to dominate the cardiac biomarkers market. Cardiac diseases have been identified as the leading cause of mortality among the U.S. citizens. According to recent statistics from the U.S. Centers for Disease Control and Prevention (CDC), CVDs account for 610,000 deaths in the U.S every year.
The fatality from heart diseases has been deemed to be high in North America. Cardiovascular diseases present a huge socioeconomic burden to the people of the United States, which has enlarged the demand for cardiac disease diagnostics.
In response to this high demand, the cardiac biomarkers field, which comprises prime indicators of fatal heart diseases, such as acute myocardial infarction and congestive heart failure is expected to grow. After the implementation of the Affordable Care Act, Medicaid coverage has grown significantly.
Reasons to subscribe to North America cardiac biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America cardiac biomarkers market databook
-
Our clientele includes a mix of cardiac biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America cardiac biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into North America cardiac biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America cardiac biomarker market size, by country, 2018-2030 (US$M)
North America Cardiac Biomarkers Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
